In this review, first principles of positron emission tomography (PET) and single photon emission tomography (SPECT) are discussed together with the relative strengths and weaknesses of both techniques. With both modalities it is possible to image and, especially with PET, to measure regional tissue function, the particular function being interrogated depending on the actual tracer being used. In the second part, the use of PET for neuroactivation studies is presented, illustrated with some key examples from the literature using both perfusion and metabolism tracers. It is argued that the future of PET (and SPECT) neuroactivation studies lies in the use of ligands. Possible approaches for performing ligand activation studies are discussed.
Introduction
At present, there is such an interest in neuroactivation studies that the term 'functional imaging' is often equated with imaging the change in cerebral activity following the presentation of a stimulus. This terminology is probably, at least in part, due to the use of the term 'functional MRI' (fMRI), which is used to distinguish it from 'standard (structural) MRI'. However, for two of the first techniques being able to image neuroactivation tomographically, positron emission tomography (PET) and single photon emission tomography (SPECT), the use of the term 'functional imaging' solely for imaging flow and/or oxygenation changes is a severe underestimation of their potential.
Positron emission tomography
PET is a tomographic imaging technique that allows for accurate non-invasive in-vivo measurements of a whole range of regional tissue functions in man. By using different tracers, a multitude of physiological, biochemical and pharmacokinetic parameters can be measured. These include blood flow (perfusion), blood volume (vascularity), oxygen utilisation, glucose metabolism, pre-and post-synaptic receptor density and affinity, neurotransmitter release, enzyme activity, drug delivery and uptake, gene expression, etc. This flexibility is a result of the fact that, in principle, nearly all biological molecules can be labelled with positron emitters such as carbon -11, nitrogen-13 and oxygen-15. In addition, fluorine-18 is often used as a substitute of hydrogen, which itself does not have an isotope suitable for in-vivo use.
Apart from flexibility, PET is also characterised by the ability to measure regional tissue tracer concentrations with high degrees of accuracy and sensitivity. This is based on the decay characteristics of positron emitters. In tissue, the emission of a positron effectively results in the simultaneous emission of two gamma rays, each with a fixed energy of 511 keV. These two annihilation photons are emitted in opposite directions and are recorded by coincidence detection (i.e. simultaneous detection by two opposing detectors). These two detectors define the line of response along which the original annihilation took place. In other words, no lead collimators are needed, thereby providing for optimal sensitivity. As the total path length of both annihilation photons together is also known, accurate correction for tissue attenuation can be made using a separate transmission scan.
At present, PET represents the most selective and sensitive (pico-to nano-molar range) method for measuring molecular pathways and interactions in vivo (Jones, 1996) . Apart from its capacity to provide new pathophysiological information on human disease, PET is also important for the objective assessment of therapeutic efficacy and plays an ever increasing role in the development of new drugs (Comar, 1995) . Finally, in those cases where it is difficult to determine whether a change is due to progression of disease or to side-effects of (chronic) medication, studies can be performed in animal models of disease .
Single photon emission tomography
SPECT differs from PET in that use is made of gamma (single photon) emitters. This mode of detection suffers from a number of disadvantages compared with PET. Firstly, when a detector registers an event, there is no information about the direction of the incoming photon. To obtain positional information, use is made of lead collimators. The collimator guarantees that only photons from a predefined direction are accepted. The lead collimator, however, results in a significant reduction in sensitivity. Further disadvantages are that both sensitivity and spatial resolution are position-dependent, that is they both decrease with increasing depth in the body. As the path length through tissue is not known, attenuation correction methods are more cumbersome than in PET. Finally, there are no single photon emitting isotopes of the basic biological elements. Therefore, use is made of radionuclides, such as Tc-99m, that are uncommon to the human body. The fate of a tracer labelled with Tc-99m is not necessarily the same as that of the native molecule, resulting in potential interpretation problems. For example, there are no satisfactory SPECT tracers for oxygen and glucose metabolism (PET tracers can be used with SPECT, but are not ideal due to the relatively high energy of the annihilation photons).
Of course, SPECT also has some advantages. Firstly, both equipment and radionuclides are readily available in every nuclear medicine department. Radionuclides usually have such a long half-life that they can be bought commercially or can be eluted from a generator. This is in contrast to PET where, due to the (very) short half-life, radionuclides usually have to be produced with an on-site cyclotron. In other words, SPECT is much cheaper and, therefore, more widely available than PET. A potentially important advantage of SPECT receptor ligands is that, in general, specific activities are much higher than those obtained with carbon-11 ligands, which cannot be made carrier-free. This can have consequences for low-density receptor studies.
Neuroactivation studies
Functional brain imaging using radioactive inert gases was pioneered by Lassen and coworkers in the late 1950s. A few years later, a quantitative method for the determination of regional cerebral blood flow was described (Ingvar & Lassen, 1961) . The method was developed further to a tomographic technique using SPECT and Xe-133. This method was subsequently applied to initial investigations of the visual system in normal controls (Henriksen, Paulson, & Lassen, 1981) .
During the 1970s, PET emerged as an accurate method for measuring regional cerebral blood flow and metabolism. In the early 1980s, studies were performed to demonstrate regional changes in both perfusion and metabolism following a stimulus. Initially, analysis consisted of subtracting a stimulus from a baseline image. Later, sophisticated statistical packages (e.g. Statistical Parametric Mapping) were developed (Friston et al., 1995) . These packages are now in regular use not only for PET, but also for fMRI studies. The early studies clearly demonstrated two important issues. Firstly, the change in perfusion was associated with a similar change in glucose metabolism, but there was an uncoupling with oxygen utilisation, which increased to a much smaller extent (Fox & Raichle, 1986) . Even now, the mechanism of this uncoupling is a matter of debate. Secondly, it was realised early on that control of the stimulus was of vital importance for interpreting signals. A classical example was the difference in activation seen in normal controls and professional musicians when listening to a piece of music (Mazziotta, Phelps, Carson, & Kuhl, 1982) .
Measurement of glucose metabolism using 18 FDG can be useful in assessing whether a certain treatment has had any effect on global and regional metabolism. It can also be used for comparing patients with normal controls and for comparing different conditions in the same subject as images with a high statistical quality can be acquired. The relatively long half-life of fluorine-18 ( 2 h) precludes repeat measurements in one scanning session and results in a somewhat higher radiation burden to the subject. Similar drawbacks apply to studies with SPECT flow tracers. Nevertheless, metabolic studies using 18 FDG have significantly contributed to the development of neuroactivation studies in PET. Mapping of visual cortex metabolism following visual stimulation was one of the first studies to be reported in this new field of research (Phelps, Kuhl, & Mazziotta, 1981 ; see Fig. 1 ).
The method of choice for repeat measurements in the same subject is the use of H 2 15 O due to its short half-life of 2 min. Initially, studies were performed in a quantitative manner, i.e. regional cerebral blood flow (CBF) was measured on a pixel-by-pixel level. Quantification of perfusion, however, requires measurement of the input function (i.e. arterial cannulation; Lammertsma et al., 1990) , which is cumbersome, especially in normal controls. A detailed knowledge of the tracer kinetics of H 2 15 O indicated that studies could also be performed on a qualitative basis, as there was a predictable relationship between uptake of H 2 15 O and actual perfusion. It should be noted, however, that 'qualitative' activation studies require reproducible tracer injections (i.e. timing, duration, volume), preferably using an infusion pump. In addition, similar to most other 'functional imaging' techniques, it is not possible to detect any global changes with this qualitative implementation. If there is any suspicion of global changes, then a full quantitative study is recommended.
With regard to the visual system, the first activation study using H 2
15
O was reported in 1984. In this study, it . This was calculated from the pixel-by-pixel grey value variance across all six scans divided by the difference in grey values between the two rest scans (a reflection of noise). To reduce noise, each scan was smoothed using a low-pass filter of side length 5 pixels (i.e. 10.25 mm). (c) t-statistic map showing the significance of any difference between colour and grey activated scans. In order to remove variance due to changes in global blood flow, the original scans have been normalised to a total brain blood flow of 50 ml/100 ml/min. As the study was designed to look for an area maximally responsive to colour but not to grey, a one-tailed t-test was used. (d) Map of the covariance of grey values across all six scans with the grey values of a reference pixel located in the striate cortex. In all scans, white and red represent the greatest activity/significance/covariance, and blue the least (reproduced with permission from Lueck et al., 1989) . Fig. 1 . Results of one of the first studies on regional activation of cerebral activity following a visual stimulus. In this study, 18 FDG was used to measure regional cerebral glucose metabolism. The original legend was as follows: (A) Sketches from actual brain slices at approximately the level of the cross-sectional tomographic images (4.4, 3.6, and 2.8 cm above the orbito-meatal plane). The blackened areas at the posterior of the brain indicate the approximate location of the primary (PVC) and associative (AVC) visual cortices. (B) When the eyes are closed and patched, the tissue metabolic rate is relatively low. (C) Stimulation by white light. The increasing glucose metabolic rate appears as increasing shades of grey, with black being the highest. Note the higher metabolic rate of the PVC and AVC (arrows) when the subject is being visually stimulated. The border zone between the posterior parietal cortex and the Broadmann area 19 of the AVC is also apparent when its metabolic rate is decreased in the unstimulated state. (D) Metabolic response of the visual cortex to the viewing of a complex visual scene (reproduced with permission from Phelps et al., 1981) .
was demonstrated that the increase in regional cerebral blood flow within the visual cortex depended on the rate of the visual stimulus given (Fox & Raichle, 1984) . It took some time before studies were reported in which specialised areas of the visual cortex were targeted directly by appropriate stimulus design, the first one localising the human colour area (Lueck et al., 1989;  see Fig. 2 ). Since then, numerous studies have been published, interrogating the visual system in detail (see, for example, Watson, 2000 for a review).
In recent years, there has been a shift from PET to fMRI activation studies. This is, at least in part, due to the need to administer radioactivity in PET. Although studies should, whenever possible, be performed with fMRI, there remains a place for PET, namely in those instances where a stimulus cannot easily be repeated such as in some psychiatric conditions. The future of PET activation studies, however, lies in ligands. Ligand studies usually require approximately 1 h (Cunningham & Lammertsma, 1995) , and it is difficult to repeat measurements within the same session. One possibility is to perform two separate studies ]raclopride study through a transaxial plane at the level of the striatum. The left image represents the parameter R 1 , which is the ratio of local (i.e. pixel) delivery of tracer and delivery to the reference tissue (in this case, cerebellum). The right image represents binding potential BP, which is related to the density of available receptors and the affinity of binding of the ligand to the receptor. Raclopride is an antagonist of the D 2 receptor, and the right image clearly shows a high concentration of D 2 receptors in the striatum. It should be noted that both images are parametric images, each one being a single image representing the magnitude of a (different) functional entity on a pixel-bypixel level. The images were generated from a dynamic data acquisition sequence (i.e. multiple scans over time) by applying a tracer kinetic model to each pixel (reproduced with permission from Gunn et al., 1997) . 11 C]raclopride. The priming bolus is used to achieve a steady-state [
11 C]raclopride level in tissue more rapidly. At 40 min, equilibrium has been reached, and the concentration is much higher in the receptor-rich basal ganglia compared with the receptor free cerebellum. At 40 min, 0.4 mg/kg of amphetamine was administered intravenously, producing displacement of raclopride (from the receptors, i.e. from the basal ganglia, but not from the cerebellum) due to competition with increased dopamine released in response to the amphetamine challenge. The magnitude of the activation can now be estimated from the change in basal ganglia-to-cerebellum ratio (reproduced with permission from Carson et al., 1997) . under different conditions. As it is now possible to generate functional images of receptor binding parameters (Gunn, Lammertsma, Hume, & Cunningham, 1997; see Fig. 3 ), previously mentioned statistical packages can be applied to these images, thereby directly detecting changes in binding on a pixel-by-pixel level (Koepp et al., 1998; see Fig. 4) . If studies need to be performed in a single session, activation can only be detected as a displacement of the expected tissue timeactivity curve, i.e. at a certain point in time, the ligand is displaced from the receptor by competition from an increased level of endogenous neurotransmitter that has been released as a result of the activation. Although initial attempts have been made (Friston et al., 1997) , analysis of these studies still requires a significant modelling and statistical effort. A very promising technique is the so-called bolus-plus-infusion method, in which first a bolus of the ligand is given, followed by a constant infusion (Carson et al., 1997) . The purpose of the bolus is to achieve steady-state tissue (i.e. receptor) tracer concentrations as quickly as possible. Any release of endogenous neurotransmitter will then result in a different steady state, which can be assessed on a pixel-by-pixel level. Presently, there is some experience with carbon-11-labelled raclopride for assessing pharmacologically induced dopamine release (see Fig. 5 ). Clearly, much work still needs to be done with respect to understanding observed changes (Laruelle, 2000) and in assessing whether changes due to smaller (e.g. cognitive) stimuli are large enough to be detected. If success-ful, however, results will be much more specific than present PET or fMRI activation studies, which are based on an indirect change in blood flow. Here, SPECT could also play a more prominent role as the steady-state technique is ideally tailored for the slower SPECT scanners.
